More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds

By Robin Respaut

SAN FRANCISCO, Feb 11 (Reuters) - Among early users of Novo Nordisk's NOVOb.COnew Wegovy weight-loss pill, 36% had no prior experience taking a GLP-1 medication, a new study from the health data firm Truveta found.

Of patients who started a new pill prescription, 21.1% had previously taken the injectable version of Wegovy and 15.8% switched from Eli Lilly's LLY.N Zepbound, another injectable GLP-1 medicine, according to Truveta data.

Truveta reviewed health records from 8,762 patients with evidence of a prescription for the new Wegovy pill, which was approved by the U.S. Food and Drug Administration on December 22.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.